Table 3.
Comparison of COVID-19 infected with non-infected patients.
| Infected (n = 19) | Uninfected (n = 346) | p value | |
|---|---|---|---|
| Age, years (median [IQR]) | 45.4 (34.2–58.1) | 43.4 (33.3–54.8) | 0.682 |
| Female, no. (%) | 13 (68.4) | 280 (80.9) | 0.231 |
| Diagnosis | 0.868 | ||
| MS, no. (%) | 13 (68.4) | 218 (63.0) | 0.808 |
| AQP4-NMOSD, no. (%) | 5 (26.3) | 101 (29.2) | 1.000 |
| MOGAD, no. (%) | 1 (5.3) | 27 (7.8) | 1.000 |
| Disease duration, years (median [IQR]) | 6.6 (4.4 – 11.6) | 7.6 (3.3 – 12.8) | 0.831 |
| EDSS ≥6, no. (%) | 6 (31.6) | 68 (19.7) | 0.240 |
| DMT use, no. (%) | 11 (57.9) | 247 (71.4) | 0.208 |
| Rituximab, no. (%) | 3 (15.8) | 44 (12.7) | 0.722 |
| Interferons, no. (%) | 2 (10.5) | 25 (7.2) | 0.642 |
| Fingolimod, no. (%) | 1 (5.3) | 16 (4.6) | 0.605 |
| Cladribine, no. (%) | 1 (5.3) | 24 (6.9) | 1.000 |
| Alemtuzumab, no. (%) | 1 (5.3) | 6 (1.7) | 0.314 |
| Azathioprine, no. (%) | 1 (5.3) | 33 (9.5) | 1.000 |
| Mycophenolate, no. (%) | 1 (5.3) | 45 (13.0) | 0.488 |
| Prednisolone, no. (%) | 1 (5.3) | 5 (1.4) | 0.276 |
| Received Pfizer vaccine for first two doses, no. (%) | 18 (94.7) | 309 (89.3) | 0.706 |
| Not received third mRNA vaccine, no. (%) | 18 (94.7) | 175 (50.6) | <0.001 |
Abbreviations: AQP4-NMOSD, aquaporin-4-antibody neuromyelitis optica spectrum disorder; DMT, disease-modifying therapy; EDSS, expanded disability status scale; IQR, interquartile range; MOGAD, myelin oligodendrocyte glycoprotein-antibody associated disease; MS, multiple sclerosis.